DMPI

DelMar Pharmaceuticals Stock Price

0.693
0.0484 (7.51%)
Upgrade to Real-Time
Regular Market
0.693
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
DelMar Pharmaceuticals Inc DMPI NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0484 7.51% 0.693 0.6446 0.706 0.6614 0.6446 15:31:22
Bid Price Ask Price Spread Spread % News
0.6901 0.693 0.0029 0.42% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
423 173,844 $ 0.6780552 $ 117,876 976,831 0.38 - 2.66
Last Trade Time Type Quantity Stock Price Currency
15:32:34 6 $ 0.693 USD

DelMar Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.90M 11.43M 9.98M $ - $ - -3.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

DelMar Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DMPI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.68520.70790.610.6601606216,5000.00781.14%
1 Month1.211.930.610.971399908,197-0.517-42.73%
3 Months0.541.930.49520.8879501637,3850.15328.33%
6 Months0.6451.930.380.7993759402,2270.0487.44%
1 Year1.642.660.380.9323535546,070-0.947-57.74%
3 Years21.60628.400.386.01471,386-20.91-96.79%
5 Years6.80108.700.387.49304,373-6.11-89.81%

DelMar Pharmaceuticals Description

DelMar Pharmaceuticals Inc is a clinical and commercial-stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. The company's principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. It also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. All the business activity of the firm is functioned through the region of Canada.


Your Recent History
NASDAQ
DMPI
DelMar Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.